Back to results
US 8,685,408 B2Granted
Compositions comprising a B subunit of Shiga toxin and a means stimulating NKT cells
AssigneesUniversite Rene Descartes Paris 5, Institut Curie, Assistance Publique-Hopitaux de Paris, Centre National de la Recherche Scientifique (CNRS)
InventorEric Tartour
Life of this patent
Estimating the term…
Abstract
The present invention relates to a composition comprising a) a B subunit of Shiga toxin or a functional equivalent thereof which is able to bind the Gb3 receptor, complexed with an antigen and b) at least one ligand of CDI capable of stimulating NK T cells; and to a pharmaceutical composition and a medicament comprising said composition.
Claims24
A composition comprising
- a) a B subunit of Shiga toxin or a functional equivalent thereof which binds to the Gb3 receptor, complexed with an antigen and
- b) at least one ligand of CD1 that stimulates NK T cells wherein said ligand is a glycolipid, a phospholipid, a glycosphingolipid, a derivative or an analog thereof, wherein said composition breaks tolerance against self antigens and stimulates dendritic cells and wherein there is synergy between said B subunit of Shiga toxin or a functional equivalent thereof which binds to the Gb3 receptor, complexed with an antigen and said at least one ligand of CD1 that stimulates NK T cells.
A pharmaceutical kit comprising:
- a first container comprising a B subunit of Shiga toxin or a functional equivalent thereof which binds to the Gb3 receptor, complexed with an antigen and
- a) at least a second container comprising at least one ligand of CD1 that stimulates NK T cells wherein said ligand is a glycolipid, a phospholipid, a glycosphingolipid, a derivative or an analog thereof.
A composition comprising
- a) a B subunit of Shiga toxin or a functional equivalent which binds to the Gb3 receptor thereof which is able to bind the Gb3 receptor, complexed with an antigen and
- b) α-GalCer that stimulates NK T cells, wherein said composition breaks tolerance against self antigens, stimulates dendritic cells and elicits antiviral immunity, wherein there is synergy between said B subunit of Shiga toxin or a functional equivalent thereof which binds to the Gb3 receptor, complexed with an antigen and said α-GalCer that stimulates NK T cells.
Dependencies are inferred from the claim text.